Evidence map›Paper›PMID 30385734›Full record

Trial reportJCI insight2018

Dietary protein restriction reduces circulating VLDL triglyceride levels via CREBH-APOA5-dependent and -independent mechanisms.

J Humberto Treviño-Villarreal, Justin S Reynolds, Alexander Bartelt, P Kent Langston, Michael R MacArthur, Alessandro Arduini, Valeria Tosti, Nicola Veronese, Beatrice Bertozzi, Lear E Brace and 16 more

Registry-linked trialOpen access · goldAbstract readClinical Trial
In one paragraph

Trial report in JCI insight, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT01692587 (Does Protein Restriction Inhibit Prostrate Cancer Growth), which is not on this map. Cited by 29 papers.

0numbers the graph read from it
0cells of the map it votes in
29citing papers in PubMed
3.1field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT01692587 nacompletednot on this map

Does Protein Restriction Inhibit Prostrate Cancer Growth

TypeinterventionalSponsorWashington University School of MedicineRan2011 to 2015Enrolled65ConditionsProstate CancerArmsProtein restrictive diet
3 · Its place in the literature

Who cites it

29 citing papers in PubMed, 51 citations in OpenAlex.

  1. Trial
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Biomedicines · 2024
    Review
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Review
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

26 authors at 6 institutions in 5 countries.

J Humberto Treviño-VillarrealDepartment of Genetics and Complex Diseases, Harvard T.H. Chan School of Public Health, Boston, Massachusetts, USA.
Justin S ReynoldsDepartment of Genetics and Complex Diseases, Harvard T.H. Chan School of Public Health, Boston, Massachusetts, USA.
Alexander BarteltDepartment of Genetics and Complex Diseases, Harvard T.H. Chan School of Public Health, Boston, Massachusetts, USA.
P Kent LangstonDepartment of Genetics and Complex Diseases, Harvard T.H. Chan School of Public Health, Boston, Massachusetts, USA.
Michael R MacArthurDepartment of Genetics and Complex Diseases, Harvard T.H. Chan School of Public Health, Boston, Massachusetts, USA.
Alessandro ArduiniDepartment of Genetics and Complex Diseases, Harvard T.H. Chan School of Public Health, Boston, Massachusetts, USA.
Valeria TostiDepartment of Medicine, Washington University in St. Louis, St. Louis, Missouri, USA.
Nicola VeroneseDepartment of Medicine, Washington University in St. Louis, St. Louis, Missouri, USA.
Beatrice BertozziDepartment of Medicine, Washington University in St. Louis, St. Louis, Missouri, USA.
Lear E BraceDepartment of Genetics and Complex Diseases, Harvard T.H. Chan School of Public Health, Boston, Massachusetts, USA.
Pedro MejiaDepartment of Genetics and Complex Diseases, Harvard T.H. Chan School of Public Health, Boston, Massachusetts, USA.
Kaspar TrochaDepartment of Genetics and Complex Diseases, Harvard T.H. Chan School of Public Health, Boston, Massachusetts, USA.
Gustavo S KajitaniDepartment of Genetics and Complex Diseases, Harvard T.H. Chan School of Public Health, Boston, Massachusetts, USA.
Alban LongchampDepartment of Genetics and Complex Diseases, Harvard T.H. Chan School of Public Health, Boston, Massachusetts, USA.
Eylul HarputlugilDepartment of Genetics and Complex Diseases, Harvard T.H. Chan School of Public Health, Boston, Massachusetts, USA.
Rose GathunguDivision of Sleep and Circadian Disorders, Department of Medicine, Brigham and Women's Hospital, Boston, Massachusetts.
Susan S BirdDepartment of Neurosurgery, Brigham and Women's Hospital, Boston, Massachusetts, USA.
Arnold D BullockDivision of Urology, Washington University School of Medicine, St. Louis, Missouri, USA.
Robert S FigenshauDivision of Urology, Washington University School of Medicine, St. Louis, Missouri, USA.
Gerald L AndrioleDivision of Urology, Washington University School of Medicine, St. Louis, Missouri, USA.
Andrew ThompsonDana Farber Cancer Institute/HMS Rodent Histopathology Core Facility, HMS, Boston, Massachusetts, USA.
Jöerg HeerenDepartment for Biochemistry and Molecular Cell Biology, University Medical Center Hamburg-Eppendorf, Germany.
C Keith OzakiDivision of Vascular and Endovascular Surgery, Department of Surgery, and.
Bruce S KristalDivision of Sleep and Circadian Disorders, Department of Medicine, Brigham and Women's Hospital, Boston, Massachusetts.
Luigi FontanaDepartment of Medicine, Washington University in St. Louis, St. Louis, Missouri, USA.
James R MitchellDepartment of Genetics and Complex Diseases, Harvard T.H. Chan School of Public Health, Boston, Massachusetts, USA.
Harvard University · USWashington University in St. Louis · USBrigham and Women's Hospital · USDana-Farber Cancer Institute · USThe University of Sydney · AUUniversität Hamburg · DE

Funding

WU INSTITUTE OF CLINICAL AND TRANSLATIONAL SCIENCESUL1TR002345 · NCATS · WASHINGTON UNIVERSITY · PI William G. Powderly · 2017 to 2026
$97.8M
Washington University Institute of Clinical and Translational Sciences (UL1)UL1RR024992 · NCRR · WASHINGTON UNIVERSITY · PI EVANOFF, BRADLEY A · 2007 to 2011
$45.4M
Washington University Institute of Clinical and Translational SciencesUL1TR000448 · NCATS · WASHINGTON UNIVERSITY · PI EVANOFF, BRADLEY A · 2012 to 2016
$41.4M
Mechanisms of dietary control of the transsulfuration pathway and increased endogenous hydrogen sulfide productionR01DK090629 · NIDDK · HARVARD SCHOOL OF PUBLIC HEALTH · PI MITCHELL, SARAH JAYNE · 2011 to 2019
$3.0M
Protection against renal ischemic injury by short term dietary restrictionR01AG036712 · NIA · HARVARD SCHOOL OF PUBLIC HEALTH · PI MITCHELL, JAMES R. · 2010 to 2014
$1.6M
Dietary restriction promotes vascular health through hydrogen sulfide-mediated angiogenesisR56AG036712 · NIA · HARVARD SCHOOL OF PUBLIC HEALTH · PI MITCHELL, JAMES R. · 2017 to 2017
$398k
NCATS NIH HHS UL1 TR000448NCATS NIH HHS UL1 TR002345NCRR NIH HHS UL1 RR024992NIA NIH HHS R01 AG036712NIA NIH HHS R56 AG036712NIDDK NIH HHS R01 DK090629
6 · The paper itself

Abstract

Hypertriglyceridemia is an independent risk factor for cardiovascular disease. Dietary interventions based on protein restriction (PR) reduce circulating triglycerides (TGs), but underlying mechanisms and clinical relevance remain unclear. Here, we show that 1 week of a protein-free diet without enforced calorie restriction significantly lowered circulating TGs in both lean and diet-induced obese mice. Mechanistically, the TG-lowering effect of PR was due, in part, to changes in very low-density lipoprotein (VLDL) metabolism both in liver and peripheral tissues. In the periphery, PR stimulated VLDL-TG consumption by increasing VLDL-bound APOA5 expression and promoting VLDL-TG hydrolysis and clearance from circulation. The PR-mediated increase in Apoa5 expression was controlled by the transcription factor CREBH, which coordinately regulated hepatic expression of fatty acid oxidation-related genes, including Fgf21 and Ppara. The CREBH-APOA5 axis activation upon PR was intact in mice lacking the GCN2-dependent amino acid-sensing arm of the integrated stress response. However, constitutive hepatic activation of the amino acid-responsive kinase mTORC1 compromised CREBH activation, leading to blunted APOA5 expression and PR-recalcitrant hypertriglyceridemia. PR also contributed to hypotriglyceridemia by reducing the rate of VLDL-TG secretion, independently of activation of the CREBH-APOA5 axis. Finally, a randomized controlled clinical trial revealed that 4-6 weeks of reduced protein intake (7%-9% of calories) decreased VLDL particle number, increased VLDL-bound APOA5 expression, and lowered plasma TGs, consistent with mechanistic conservation of PR-mediated hypotriglyceridemia in humans with translational potential as a nutraceutical intervention for dyslipidemia.

Indexed as

AnimalsApolipoprotein A-VApolipoproteinsCyclic AMP Response Element-Binding ProteinDiet, Protein-RestrictedFemaleHumansHydrolysisHypertriglyceridemiaLipid MetabolismLipoproteins, VLDLLiverMaleMechanistic Target of Rapamycin Complex 1MiceProtein Serine-Threonine KinasesApoa5 protein, mouseApolipoprotein A-VApolipoproteinsCreb3l3 protein, mouseCyclic AMP Response Element-Binding ProteinEif2ak4 protein, mouseLipoproteins, VLDLMechanistic Target of Rapamycin Complex 1Protein Serine-Threonine KinasesTriglyceridesvery low density lipoprotein triglycerideLipoproteinsMetabolism

Identifiers

PMID30385734
PMCPMC6238732
OpenAlexW2899440748

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.